CONMED (NYSE:CNMD) Issues Earnings Results

CONMED (NYSE:CNMD - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.95 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.14, Zacks reports. CONMED had a net margin of 10.13% and a return on equity of 14.31%. The company had revenue of $321.26 million during the quarter, compared to the consensus estimate of $313.38 million. During the same quarter in the previous year, the firm posted $0.79 earnings per share. CONMED's revenue for the quarter was up 2.9% compared to the same quarter last year. CONMED updated its FY 2025 guidance to 4.450-4.600 EPS.

CONMED Stock Performance

NYSE:CNMD traded down $0.74 during trading hours on Monday, reaching $56.94. 488,618 shares of the company's stock were exchanged, compared to its average volume of 452,489. The company has a quick ratio of 1.06, a current ratio of 2.30 and a debt-to-equity ratio of 0.94. CONMED has a 1-year low of $46.00 and a 1-year high of $78.58. The company has a 50-day moving average of $56.10 and a 200 day moving average of $64.78. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of 13.43, a P/E/G ratio of 1.83 and a beta of 1.19.

CONMED Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 4th. Shareholders of record on Friday, March 14th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 1.41%. The ex-dividend date of this dividend was Friday, March 14th. CONMED's dividend payout ratio is currently 21.05%.

Wall Street Analysts Forecast Growth

CNMD has been the topic of a number of recent analyst reports. Stifel Nicolaus downgraded shares of CONMED from a "buy" rating to a "hold" rating and lowered their price target for the stock from $75.00 to $55.00 in a report on Monday, April 28th. Needham & Company LLC reduced their price objective on CONMED from $91.00 to $61.00 and set a "buy" rating for the company in a research note on Thursday. JPMorgan Chase & Co. lowered their price target on shares of CONMED from $70.00 to $58.00 and set a "neutral" rating on the stock in a research report on Thursday. Finally, Wells Fargo & Company dropped their price objective on shares of CONMED from $70.00 to $57.00 and set an "equal weight" rating for the company in a report on Thursday. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $62.20.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.